ClinicalTrials.gg
CompletedNCT06189066LOCUSUpdated Jan 7, 2026

Long COVID Ultrasound Trial

An interventional study of Splenic Ultrasound in Long Covid, sponsored by SecondWave Systems Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by SecondWave Systems Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Enrollment
132nd of 156
15 · median 53
Started
2024
with 42 others
No phase
78 of 195
23 open now
Registered
117th of 195
by date

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 132nd largest by enrollment of the 156 interventional ones that give a count, is one of 43 that started in 2024, is one of 78 with no phase, and was the 117th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study.

Specific Aims include:

  • Measure Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation.
  • Measure molecular correlates of Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation.
  • Track adverse events throughout the study to assess safety of the ultrasound intervention.
Read the detailed description

Ultrasound is widely used in human medicine because it is safe, non-invasive, and painless. The same kind of ultrasound that is used for imaging (for example, to visualize babies in utero) may be able to treat inflammatory diseases including Long COVID.

In Long COVID, there can be a state of hyperinflammation that persists in those with symptoms months to years after infection. This hyperinflammatory state includes elevated proinflammatory cytokines such as interferon β (IFN-β), IFN-λ1, IFN-γ, CXCL9, CXCL10, interleukin-6 (IL-6), IL-8, IL-1β , and Tumor Necrosis Factor (TNF-α) in those with Long COVID. Prolonged inflammation in those with Long COVID plays a key role in its pathogenesis and in driving the persistent symptoms.

This study will employ investigational ultrasound devices produced by SecondWave Systems called the MINI ultrasound system.

This is a pilot single-arm intervention study in which up to 15 study participants will receive noninvasive splenic ultrasound therapy over eight weeks (five daily stimulation sessions per week). Participants will be enrolled in the study for a total of 12 weeks starting at Week 0. They will undergo a 4-week Baseline Period during which no intervention is delivered to determine how study outcomes may change over time. Then, after baseline outcomes are measured at Week 4, the investigational ultrasound interventional period will begin. Outcomes will be compared from baseline at Week 4 through the end of the 8-week intervention period at Week 12. Investigational splenic-ultrasound therapy will be delivered with the SecondWave MINI ultrasound system. The objective of the study is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study.

For ultrasound stimulation, a small wearable ultrasound device is positioned on the upper left abdomen area over the ribs. Study personnel will use an ultrasound imaging device to locate the spleen and to position the wearable MINI device in a proper location around the ribs area. Daily stimulation consists of an approximately 18-minute period for application of ultrasound to the spleen. Collection of long-COVID outcome data, patient-reported assessments, and blood draws collected at the 6 study visits to assess biomarkers of inflammation will be performed in each participant throughout the study. Stool samples will be collected at 4 timepoints to assess changes in microbiome and metabolomics over the study period. Movement activity and sleep monitoring will be collected throughout the day and correlated with other study outcomes.

The study's primary outcome measure is the endurance shuttle walk test (ESWT) and the secondary outcome measure is the Chalder fatigue scale (CFQ-11). We will also investigate exploratory outcomes that will include other activity outcomes (e.g., total movement per day, sleep patterns), vital signs (e.g. heart rate and blood pressure), biomarker assessments (e.g., CRP, ESR, cortisol), cytokine assessments, microbiome and metabolomic related assessments, and device usability and experience assessments.

03

Conditions studied

  • Long Covid

Keywords

  • long covid
  • covid-19
  • long-haul COVID
  • post-COVID conditions (PCC)
  • post-acute COVID-19
  • post-acute sequelae of SARS-CoV-2 infection (PASC)
  • ultrasound
  • ultrasound stimulation
  • ultrasound treatment
  • ultrasound therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years at the time of enrollment
  2. Prior diagnosis of COVID-19 by report, PCR, or home kit
  3. Symptoms present for 12 or more weeks that are independent prior to SARS-CoV-2 infection including fatigue and one or more of:

    1. Myalgia or general aches/pains
    2. Joint pain
    3. Dizziness/lightheadedness
    4. Cognitive dysfunction (brain fog)

Exclusion criteria

Exclusion Criteria:

  1. Candidate who is unable or unwilling to postpone taking new medications used for treating Long COVID during the study period
  2. Candidate that is currently taking immune modifying medications and unable to maintain stable levels of their immune medication regimen throughout the study period
  3. History of intubation secondary to COVID-19
  4. ICU admission for COVID-19
  5. Pre-existing Lung conditions such as (COPD), interstitial lung disease (ILD), or severe asthma
  6. Pregnant
  7. History of coronary artery disease (CAD)
  8. History of stroke
  9. History of severe anemia of less than 8 g/dl
  10. Prior history of Lyme disease
  11. Prior history cognitive impairment
  12. Any non-marijuana drug abuse history within 30 days
  13. Current use of an drug
  14. History of prior myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS)
  15. History of alcohol abuse: greater than 2 drinks a day for men and 1 drink for females
  16. Prior history of postural orthostatic tachycardia syndrome (POTS)
  17. Chronic fatigue secondary to any condition other than COVID-19.
  18. Fibromyalgia
  19. History of prior chronic pain
  20. History of chronic liver disease such as cirrhosis
  21. History of splenic pathology such as spleen infarct/splenomegaly
  22. History of splenectomy
  23. History of Sickle disease with splenic pathology
  24. Taking non-approved treatments for Long COVID
  25. Participant does not speak English
  26. Participant is an active member of the military (service member) or DoD personnel (including civilian employees)
  27. Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Ultrasound Group

    Device: Splenic Ultrasound

Interventions

  • DeviceSplenic Ultrasound

    Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.

    Also known as: SecondWave Systems investigational MINI device

06

What researchers measure

Primary outcomes

  1. Within-arm change in the endurance shuttle walk test (ESWT) from baseline to the completion of an up-to 8-week intervention period.

    ESWT is a standardized, externally controlled, constant-paced walking test for the assessment of endurance capacity. Improvement in this outcome will be determined by an increase of distance walked and/or increase in time walked before failure to maintain the controlled walking pace.

    Time frame: 8 weeks

Secondary outcomes

  1. Within-arm change in the Chalder fatigue scale (CFQ-11; Likert score) from baseline to the completion of an up-to 8-week intervention period.

    CFQ-11 is a is a self-administered questionnaire for measuring the extent and severity of fatigue.

    Time frame: 8 weeks

  2. Track adverse events throughout the study to assess the safety of the ultrasound intervention.

    Time frame: 8 weeks

07

Study locations

1 site
  • University of Minnesota - Phillips-Wangensteen Building
    Minneapolis, Minnesota 55455, United States
08

References and documents

Publications

  • Goggins E, Inoue H, Okusa MD. Neuroimmune Control of Inflammation in Acute Kidney Injury and Multiorgan Dysfunction. J Am Soc Nephrol. 2025 Dec 1;36(12):2473-2484. doi: 10.1681/ASN.0000000813. Epub 2025 Jul 7. PubMed 40622772 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Of 243 interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2023
First posted
Jan 3, 2024
StartActual
Jan 3, 2024
Primary completionActual
Jul 24, 2024
CompletionActual
Jul 24, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06189066
Lead sponsor
SecondWave Systems Inc.
Collaborators
University of Minnesota, United States Department of Defense
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Jan 3, 2024
Primary completion
Jul 24, 2024
Completion
Jul 24, 2025
Last update
Jan 7, 2026

Study contacts

Farha Ikramuddin, M.D.
principal investigator · University of Minnesota Medical School, Department of Rehabilitation Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion